Bioequivalence study followed by model-informed dose optimization of a powder for oral suspension of 6-mercaptopurine.

6MP PFOS 10 mg/mL should be administered at a 20% lower dose than the tablet to achieve comparable exposure. 6MP PFOS addresses an unmet medical need for a liquid formulation of 6MP in the Indian subcontinent.